MARKET

ARQT

ARQT

Arcutis Biotherapeutics, Inc.
NASDAQ
29.61
-0.59
-1.95%
Opening 14:56 01/06 EST
OPEN
30.01
PREV CLOSE
30.20
HIGH
30.44
LOW
29.13
VOLUME
821.28K
TURNOVER
--
52 WEEK HIGH
31.77
52 WEEK LOW
11.13
MARKET CAP
3.63B
P/E (TTM)
-83.5497
1D
5D
1M
3M
1Y
5Y
1D
Arcutis Biotherapeutics - Focusing On ZORYVE Market Expansion And Pipeline Growth
NASDAQ · 8h ago
Weekly Report: what happened at ARQT last week (1229-0102)?
Weekly Report · 1d ago
Top Arcutis Insider Makes Head-Turning Stock Move
TipRanks · 3d ago
Wednesday's ETF Movers: XBI, SLVR
NASDAQ · 12/31/2025 17:54
Weekly Report: what happened at ARQT last week (1222-1226)?
Weekly Report · 12/29/2025 10:12
Sustained Zoryve Prescription Momentum and Broad Dermatology Portfolio Underpin Buy Rating and $37 Target on Arcutis Biotherapeutics
TipRanks · 12/26/2025 13:25
Does Suvretta’s Trim and ZORYVE’s Pediatric Progress Change The Bull Case For Arcutis (ARQT)?
Simply Wall St · 12/25/2025 11:26
2025 Performance Review And Future Strategy
Seeking Alpha · 12/22/2025 13:30
More
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.

Webull offers Arcutis Biotherapeutics Inc stock information, including NASDAQ: ARQT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARQT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARQT stock methods without spending real money on the virtual paper trading platform.